Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients
Wollina U, Hansel G, Koch A, et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9:1-14.
Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases
Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat.2009;20:100-108.
New onset psoriasis in a patient receiving abatacept for rheumatoid arthritis
[published online ahead of print March 6]. pii:bcr09.2008.0845
Jost C, Hermann J, Caelen Lel-S, et al. New onset psoriasis in a patient receiving abatacept for rheumatoid arthritis [published online ahead of print March 6, 2009]. BMJ Case Rep. pii:bcr09.2008.0845.
A case of generalized guttate psoriasis induced by etanercept with relapse after abatacept [letter]
Brigant F, Clavel G, Chatelain D, et al. A case of generalized guttate psoriasis induced by etanercept with relapse after abatacept [letter]. Dermatol Online J.2011;17:11.
A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci
Liu Y, Helms C, Liao W, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet. 2008;4:e1000041.
Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells
Ma HL, Napierata L, Stedman N, et al. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis and Rheum. 2010;62:430-440.